



2023 HIV Prevention Drug Chart

This quick reference chart compares antiretroviral (ARV) options for the prevention of HIV, including adult dosing information.

May 15, 2023

Pre-Exposure Prophylaxis (PrEP)

[PrEP](#) is an antiretroviral medication taken by an HIV-negative person to reduce the risk of contracting HIV. The Food and Drug Administration has approved the following three regimens for PrEP:

DRUG	ADULT DOSING INFO	APPROVED FOR
Truvada (tenofovir disoproxil fumarate + emtricitabine)	One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate (TDF) + 200 mg emtricitabine.	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV. Generic version available.
Descovy (tenofovir alafenamide fumarate + emtricitabine)	One tablet once a day. Each tablet contains 25 mg tenofovir alafenamide fumarate (TAF) + 200 mg emtricitabine.	Not approved for those at risk for HIV acquisition via vaginal sex.
Apretude (cabotegravir)	Apretude is initiated with two 600 mg injections given one month apart for the first two months, after which injections are given every two months. Alternatively, oral cabotegravir (Vocabria) may be taken for four weeks before the injections. Apretude is given as a single injection in the buttocks by a health care worker every other month.	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV.

DRUG: [Truvada](#) (tenofovir disoproxil fumarate + emtricitabine)

ADULT DOSING INFO	One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate (TDF) + 200 mg emtricitabine.
APPROVED FOR	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV. Generic version available.

DRUG: [Descovy](#) (tenofovir alafenamide fumarate + emtricitabine)

ADULT DOSING INFO	One tablet once a day. Each tablet contains 25 mg tenofovir alafenamide fumarate (TAF) + 200 mg emtricitabine.
-------------------	--

DRUG: [Descovy](#) (tenofovir alafenamide fumarate + emtricitabine)

APPROVED FOR Not approved for those at risk for HIV acquisition via vaginal sex.

DRUG: [Apretude](#) (cabotegravir)

ADULT DOSING INFO	Apretude is initiated with two 600 mg injections given one month apart for the first two months, after which injections are given every two months. Alternatively, oral cabotegravir (Vocabria) may be taken for four weeks before the injections. Apretude is given as a single injection in the buttocks by a health care worker every other month.
APPROVED FOR	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV.

Post-Exposure Prophylaxis (PEP)

[PEP](#) involves taking a short course of ARV drugs, usually for a month, after a high-risk exposure. For maximum effectiveness, PEP should be started immediately—and no more than 72 hours—after possible exposure. The Centers for Disease Control and Prevention recommends the following preferred HIV PEP regimen:

DRUG	DOSING INFO
Isentress (raltegravir)	One tablet twice a day. Each tablet contains 400 mg of raltegravir.

DRUG: [Isentress](#) (raltegravir)

DOSING INFO One tablet twice a day. Each tablet contains 400 mg of raltegravir.

PLUS

DRUG	DOSING INFO
Truvada (tenofovir disoproxil fumarate + emtricitabine)	One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate + 200 mg emtricitabine

DRUG: [Truvada](#) (tenofovir disoproxil fumarate + emtricitabine)

DOSING INFO One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate + 200 mg emtricitabine

Alternative PEP regimens can be found online in the [CDC's PEP Guidelines](#).

[Click here](#) for a printable version of this drug chart.

[Click here](#) for more information on HIV prevention.